title: [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
abstract: TOBI Podhaler is the first dry powder formulation of tobramycin for inhaled therapy of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients from the age of 6 years. Clinical studies show a safety and efficacy profile comparable to tobramycin inhaled solution (TOBI). The short administration time and the convenient use of the system may significantly decrease the treatment burden. This paper gives a short review of the clinical studies and some practical information.
authors.affiliation: Centre Liégeois de Reference pour la Mucoviscidose, site CHC Espérance, Liège. frederic.pierart@chc.be
authors.forename: F
authors.initials: F
authors.lastname: Pierart
mesh_terms: D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002908:Chronic Disease; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003550:Cystic Fibrosis / Q000150:complications* / Q000188:drug therapy; D058995:Dry Powder Inhalers; D006801:Humans; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa; D014031:Tobramycin / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D014031:Tobramycin